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Abstract 
Background: Vascular calcification is an independent risk factor for cardiovascular disease. Diabetes mellitus 
increases the incidence of vascular calcification; however, detailed molecular mechanisms of vascular calcification in 
diabetes mellitus remain unknown. We recently reported that bone morphogenetic protein‑binding endothelial cell 
precursor‑derived regulator (BMPER) regulates osteoblast‑like trans‑differentiation of human coronary artery smooth 
muscle cells (HCASMCs).
Methods: We investigated the effect of a hydroxymethylglutaryl‑coenzyme A reductase inhibitor (statin), commonly 
used in patients with atherosclerotic diseases and diabetes mellitus, on alkaline phosphatase (ALP) mRNA expres‑
sion in aortas of streptozotocin‑induced diabetic mice. We also investigated the effects of the statin, Rho‑associated 
protein kinase (ROCK) inhibitors and BMPER knockdown on ALP mRNA expression and activity in HCASMCs cultured 
in high glucose‑containing media.
Results: Alkaline phosphatase mRNA expression was increased in aortas of streptozotocin‑induced diabetic mice, 
and the increase was inhibited by rosuvastatin. ALP mRNA expression and activity were increased in HCASMCs 
cultured in high glucose‑containing media, and the increases were suppressed by rosuvastatin. This suppression 
was reversed by the addition of mevalonate or geranylgeranyl pyrophosphate, but not farnesyl pyrophosphate. High 
glucose‑increased ALP mRNA expression and activity were suppressed by ROCK inhibitors. Moreover, BMPER mRNA 
expression was increased in diabetic mouse aortas and in HCASMCs cultured in high glucose‑containing media, but 
was not inhibited by rosuvastatin or ROCK inhibitors. Knockdown of BMPER suppressed high glucose‑increased ALP 
activity, but not ROCK activity in HCASMCs.
Conclusions: There are at least two independent pathways in high glucose‑induced ALP activation in HCASMCs: the 
Rho–ROCK signaling pathway and the BMPER‑dependent pathway.
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Background
Vascular calcification is one of the common pathologi-
cal changes of atherosclerosis and is an independent risk 
factor for cardiovascular disease. The incidence of vascu-
lar calcification increases with aging, smoking, hemodi-
alysis, and diabetes mellitus. However, detailed molecular 
mechanisms of vascular calcification in diabetes mellitus 
remain poorly understood. In diabetes mellitus, high glu-
cose promotes trans-differentiation of vascular smooth 
muscle cells, which is thought to cause vascular calci-
fication, and hyperinsulinemia and elevated advanced 
glycosylation end products may play a role in vascular 
calcification [1].
Hydroxymethylglutaryl-coenzyme A (HMG-CoA) 
reductase inhibitors, statins, are drugs that lower cho-
lesterol levels by inhibiting HMG-CoA reductase. Statins 
are commonly used in patients with atherosclerotic dis-
eases and diabetes mellitus. It is widely recognized that 
statins have pleiotropic effects unrelated to cholesterol-
lowering effects, such as anti-inflammatory and anti-
oxidative effects [2]. In addition to inhibiting cholesterol 
synthesis, statins also block the synthesis of isoprenoid 
intermediates such as farnesyl pyrophosphate (FPP) 
and geranylgeranyl pyrophosphate (GGPP) [3]. FPP 
and GGPP serve as important lipid attachments for the 
posttranslational modification of a variety of proteins, 
including small GTPases [4]. Modification with FPP is 
necessary for proper localization of Ras family proteins, 
whereas GGPP is required for Rho, Rab, and Rap family 
proteins. In vitro studies have demonstrated that statins 
inhibit Rho by inhibiting GGPP, and thereby suppress its 
effector Rho-associated protein kinase (ROCK) [5].
It was reported that statins inhibit in  vitro calcifica-
tion of vascular smooth muscle cells induced by inor-
ganic phosphate [6], inflammatory mediators [7], 
vitamin D3 and warfarin [8], and transforming growth 
factor (TGF)-β [9]. However, with regard to the inhibi-
tory effects of statins on vascular calcification, conflict-
ing results have been reported between in vitro research 
and clinical studies. Several clinical studies using elec-
tron beam tomography have shown that statins reduce 
coronary artery calcification [10–12]. However, three 
subsequent randomized trials using electron beam 
tomography have shown no inhibitory effects of statins 
on coronary artery calcification [13–15]. Furthermore, 
a recent analysis of eight randomized trials using intra-
vascular ultrasonography showed that statins promoted 
coronary artery calcification [16].
Bone morphogenetic protein (BMP)-binding endothe-
lial cell precursor-derived regulator (BMPER) is a secre-
tory protein that is known to bind to BMP-2, 4 and 6 [17]. 
BMPER can work as either an activator or an inhibitor 
of BMP signaling, depending on its concentrations and 
environment [18]. We have reported that BMPER is a 
regulator of the osteoblast-like trans-differentiation of 
human coronary artery smooth muscle cells (HCASMCs) 
[19]. Knockdown of BMPER inhibits, whereas addition 
of BMPER enhances the osteoblast-like trans-differenti-
ation of HCASMCs.
Here, we investigated the effects of a statin, ROCK 
inhibitors and BMPER knockdown on alkaline phos-
phatase (ALP) mRNA expression and activity in 
HCASMCs cultured in high glucose-containing media to 
examine the potentially critical roles of the Rho–ROCK 




All animal experiments were approved by the Institu-
tional Animal Care and Use Committee and carried 
out according to the Kobe University Animal Experi-
mental Regulations (P140605). Streptozotocin (STZ)-
induced type I diabetic mice were produced as described 
previously [20] with slight modification. Briefly, male 
C57BL/6J mice (10-week-old) were intraperitoneally 
injected with STZ in distilled water (200  mg/kg; Wako, 
Osaka, Japan) or the equal volume of vehicle as a con-
trol. Blood samples were taken from mouse lateral tail 
vein and blood glucose was measured by OneTouch 
Ultra glucometer (LifeScan, Wayne, PA, USA). Fast-
ing blood glucose was measured at 4 and 8  days after 
the first STZ injection, and additional STZ injections 
(250  mg/kg) were given when the fasting blood glucose 
was less than 250  mg/dl. Rosuvastatin, kindly provided 
by AstraZeneca, was dissolved in drinking water, which 
was available ad  libitum, and administered with 7.2 mg/
kg body weight/day for 14  days. After being anesthe-
tized intraperitoneally with 2.5  % 2,2,2-tribromoethanol 
(1.6 ml/100 g), the mice were transcardially perfused with 
physiological saline solution and the aortas were isolated.
Cell culture
Human coronary artery smooth muscle cells (Lonza, 
Basel, Switzerland) were cultured at 37  °C in Dulbec-
co’s modified Eagle’s medium (Nacalai, Kyoto, Japan) 
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(glucose; 5.5 mM) supplemented with 15 % fetal bovine 
serum (Life Technologies, Carlsbad, CA, USA), 100  IU/
ml penicillin and 100 g/ml streptomycin (Nacalai) (nor-
mal glucose-containing media). High glucose-containing 
media (final 25 mM) was made by addition of 19.5 mM 
glucose to normal glucose-containing media. In like 
manner, 19.5  mM mannitol (Sigma-Aldrich, St. Louis, 
MO, USA) was added to normal glucose-containing 
media as an osmolality control (mannitol-containing 
media). Cells between passages 8 and 14 were used for 
the experiments. Unless otherwise noted, cells were cul-
tured for the indicated time periods without changing 
media. In some experiments, HCASMCs were cultured 
with rosuvastatin (10  µM), mevalonate (Sigma-Aldrich) 
(100 µM), FPP (Sigma-Aldrich) (10 µM), GGPP (Sigma-
Aldrich) (10  µM), fasudil (Wako) (10  µM) and Y-27632 
(Wako) (10 µM). Human umbilical vein endothelial cells 
(HUVECs) (Lonza) were cultured at 37 °C in the EGM-2 
BulletKit (Lonza).
Small interfering RNA (siRNA) experiments
Knockdown of BMPER by siRNAs was performed as 
described previously [19]. HCASMCs were transfected 
with Stealth siRNAs for BMPER (Life Technologies) 
using Lipofectamine RNAiMAX (Life Technologies) 
according to the manufacturer’s instructions. A Stealth 
siRNA non-silencing negative control (Life Technologies) 
was used as a control. Forty-eight hours after transfec-
tion, HCASMCs were subjected to each experiment.
Real‑time polymerase chain reaction (PCR)
Real-time PCR was performed as described previously 
[19]. Total mRNAs were extracted from mouse aor-
tas and HCASMCs using TRIzol Reagent (Life Tech-
nologies) and subjected to real-time PCR using a 7500 
Real-Time PCR System (Life Technologies) with a SYBR 
Premix Ex Taq II (Tli RNaseH Plus) (Takara Bio, Otsu, 
Japan). The following primers were used: mouse ALP: 
forward, 5-ACACCTTGACTGTGGTTACTGCTG 
A-3 and reverse, 5-CCTTGTAGCCAGGCCCGTTA-3; 
mouse BMPER: forward, 5-ATTACCTGCTGCGTCTT 
GCT-3 and reverse, 5-TTCTCTCACGCACTGTGTCC-3; 
mouse GAPDH: forward, 5-GACCCCTTCATTGACCTC 
AACTAC-3 and reverse, 5-TTTCTTACTCCTTGGAGGC 
CATGT-3; and human ALP: forward, 5-GGACCAT 
TCCCACGTCTTCAC-3 and reverse, 5-CCTTGTAGCC 
AGGCCCATTG-3; human BMPER: forward, 5-AGG 
ACAGTGCTGCCCCAAATG-3 and reverse, 5-TACTGAC 
ACGTCCCCTGAAAG-3; human glyceraldehyde-
3-phosphate dehydrogenase (GAPDH): forward, 5-CT 
GATGCCCCCATGTTCGTC-3 and reverse, 5-CACCCTGT 
TGCTGTAGCCAAATTC-3. Primer pairs were purchased 
from Takara Bio. GAPDH was used for standardization, and 
the comparative threshold method was used to assess the 
relative abundance of the targets.
ALP staining
Alkaline phosphatase staining was performed essen-
tially as described previously [19]. HCASMCs cultured 
in 24-well plates were washed with phosphate-buffered 
saline, and fixed in 4  % paraformaldehyde for 2  min. 
The cells were incubated in substrate working solu-
tion [100 mg/ml naphthol AS-MX phosphatase (Sigma-
Aldrich), 600  mg/ml fast red TR salt (Sigma-Aldrich), 
0.5  % (v/v) N,N-dimethylformamide, 2  mM MgCl2 and 
0.1  M Tris–HCl pH 8.8] at 37  °C for 20  min. The cells 
were washed until the intense red color became indica-
tive. The ratio of ALP-positive area was calculated from 
10 wells, with at least 500 cells counted per well, using 
ImageJ software.
Western blotting
Western blotting was performed as described previously 
[21]. ROCK activity was measured by myosin phos-
phatase target subunit 1 (MYPT1) phosphorylation as 
described previously [22]. Rabbit anti-phospho-MYPT1 
polyclonal antibody (#4563, Cell Signaling Technology, 
Danvers, MA, USA), rabbit anti-MYPT1 polyclonal anti-
body (#2634, Cell Signaling Technology) and anti-rabbit 
immunoglobulin G, horseradish peroxidase-linked whole 
antibody donkey (GE Healthcare Bioscience, Pittsburgh, 
PA, USA) were used at 1:1,000. The signals were detected 
using the Amersham Imager 600 (GE Healthcare Biosci-
ence, Little Chalfont, UK). Densitometric analysis was 
performed using ImageJ software.
Statistical analysis
All experiments were performed at least three times, and 
the results are expressed as mean ± standard error of the 
mean (SEM). Student’s t-test was used when comparing 
differences between two groups. Differences between 
more than three groups were analyzed by one-way analy-
sis of variance, followed by Tukey’s or Dunnett’s multiple 
comparison tests, as appropriate. Values of P < 0.05 were 
considered significant.
Results
Rosuvastatin decreased ALP mRNA expression in aortas 
of STZ‑induced type I diabetic mice
We investigated the effect of rosuvastatin on ALP expres-
sion in aortas of STZ-induced type I diabetic mice. 
Compared with control mice, ALP mRNA expression in 
aortas of STZ-induced type I diabetic mice given rosuv-
astatin was significantly increased (~2.0-fold; P  <  0.01). 
Administration of rosuvastatin significantly inhibited the 
increase in ALP mRNA expression (P < 0.05) (Fig. 1a).
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Rosuvastatin suppressed high glucose‑increased ALP 
mRNA expression and activity in HCASMCs
To elucidate molecular mechanisms of the inhibition of 
ALP mRNA expression in diabetic mice by rosuvasta-
tin, we performed in  vitro experiments using cultured 
HCASMCs. When HCASMCs were cultured in high 
glucose-containing media, ALP mRNA expression and 
activity were significantly increased and these increases 
were significantly suppressed by rosuvastatin (Fig.  1b, 
d). Because statins show pleiotropic effects by inhibiting 
isoprenoid synthesis, the effects of mevalonate, FPP and 
GGPP on the rosuvastatin-suppressed ALP expression 
were examined. The suppression of ALP expression by 
rosuvastatin was reversed by the addition of mevalonate 
and GGPP, but not by the addition of FPP (Fig.  1c–e). 
These results indicate that rosuvastatin suppresses high 
glucose-increased ALP mRNA expression and activity in 
HCASMCs, and that the effects of rosuvastatin are likely 
due to the inhibition of GGPP synthesis.
ROCK inhibitors suppressed high glucose‑increased ALP 
mRNA expression and activity in HCASMCs
GGPP is required for geranylgeranylation of small G 
proteins such as Rho, Rac and Cdc42 [4]. In particular, 
inhibition of Rho and its downstream target, ROCK, has 
emerged as the principle mechanism underlying the plei-
otropic effects of statins [22, 23]. We therefore focused on 
the role of the Rho–ROCK signaling pathway. To reveal 
whether ROCK is involved in high glucose-increased 
ALP expression and activity, the effects of specific ROCK 
Fig. 1 Effects of rosuvastatin, mevalonate and GGPP on high glucose‑increased ALP mRNA expression and activity. a ALP mRNA expression in 
aortas of STZ‑induced type I diabetic mice. The values represent the mean ± SEM (n = 8–11). b ALP mRNA expression in HCASMCs cultured for 
10 days. The values represent the mean ± SEM (n = 3–4). c The inhibitory effects of rosuvastatin on high glucose‑induced ALP mRNA expression, 
and reversal by mevalonate and GGPP. HCASMCs were cultured with rosuvastatin, mevalonate, FPP and GGPP for 5 days in high glucose‑containing 
media. The values represent the mean ± SEM (n = 6). d The inhibitory effects of rosuvastatin on high glucose‑induced ALP activity, and reversal by 
mevalonate and GGPP. HCASMCs were cultured for 10 days. Representative images are shown. e Percentages of the ALP‑positive area relative to the 
total surface area of HCASMCs. The data are presented as mean ± SEM (n = 5). Veh vehcle, RSV rosuvastatin, NG normal glucose, HG high glucose, M 
mannitol, Mev mevalonate. *P < 0.05; †P < 0.01; ns not significant.
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inhibitors, fasudil and Y-27632, were examined. The 
increases in ALP mRNA expression and activity by culti-
vation in high glucose-containing media were effectively 
suppressed by the ROCK inhibitors fasudil and Y-27632 
(Fig. 2a–c).
BMPER was involved in high glucose‑increased ALP activity 
in HCASMCs
We then examined whether BMPER was involved 
in high glucose-increased ALP activity. BMPER 
mRNA levels were increased by cultivation in high 
glucose-containing media, but not by mannitol 
(Fig.  3a). The high glucose-increased ALP activ-
ity was suppressed by knockdown of BMPER by siR-
NAs (Fig.  3b, c). Furthermore, BMPER mRNA levels 
were increased in aortas of STZ-induced type I dia-
betic mice by 2.5-fold (P < 0.05) (Fig. 4a). Collectively, 
these results show that BMPER mRNA expression is 
increased by cultivation in high glucose-containing 
media and in diabetic mice, and indicate the involve-
ment of BMPER in high glucose-increased ALP activ-
ity in HCASMCs.
Fig. 2 Inhibition of high glucose‑increased ALP mRNA expression and activity by ROCK inhibitors. a Inhibition of high glucose‑induced increases 
in ALP mRNA levels in HCSMCs by fasudil and Y‑27632. HCASMCs were cultured in high glucose‑containing media for 5 days. The values repre‑
sent the mean ± SEM (n = 3). b, c Inhibition of high glucose‑induced increases in ALP activity of HCSMCs by fasudil and Y‑27632. HCASMCs were 
cultured for 10 days. Representative images of the ALP‑staining (b) and the percentages of the ALP‑positive area relative to the total surface area of 
HCASMCs (c) are shown. The data are presented as mean ± SEM (n = 5). †P < 0.01.
Fig. 3 Involvement of BMPER in high glucose‑increased ALP activity. a High glucose‑induced increases in BMPER mRNA levels in HCSMCs cultured 
for 10 days. The values represent the mean ± SEM (n = 3–4). b, c Inhibition of high glucose‑induced increases in ALP mRNA levels in HCSMCs by 
BMPER knockdown. HCASMCs cultured in high glucose‑containing media for 10 days. Representative images of the ALP‑staining (b) and the per‑
centages of the ALP‑positive area relative to the total surface area of HCASMCs (c) are shown. The data are presented as mean ± SEM (n = 4–5). siC 
control siRNA, siB BMPER siRNA. *P < 0.05; †P < 0.01; ns not significant.
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BMPER‑mediated ALP activation was independent of the 
Rho–ROCK signaling pathway
To clarify the relationship between the Rho–ROCK sign-
aling pathway and BMPER in high glucose-increased 
ALP activity in HCASMCs, we first examined the effect 
of rosuvastatin on BMPER mRNA expression. BMPER 
mRNA expression was not significantly inhibited by rosu-
vastatin in mouse aortas (Fig. 4a). BMPER mRNA expres-
sion was not changed by rosuvastatin in HCASMCs, 
but was significantly increased in HUVECs (Fig.  4b). 
The increases in BMPER mRNA expression in HUVECs 
were consistent with the previous report [24]. Then, the 
effects of ROCK inhibitors on BMPER mRNA expression 
were examined. ROCK inhibitors did not inhibit the high 
glucose-increased BMPER mRNA expression (Fig.  4c). 
Collectively, these results indicate that the Rho–ROCK 
signaling pathway is not located upstream of the high 
glucose-increased BMPER mRNA expression.
Next, to reveal whether high glucose induces activa-
tion of the Rho–ROCK signaling pathway via BMPER, 
we examined MYPT1 phosphorylation. High glucose 
increased MYPT1 phosphorylation, but knockdown of 
BMPER did not inhibit MYPT1 phosphorylation (Fig. 5). 
Collectively, these results indicate that, although the 
Rho–ROCK signaling pathway is involved in high glu-
cose-induced ALP activation in HCASMCs, BMPER-
mediated signaling is another pathway independent of 
the Rho–ROCK signaling pathway.
Finally, the inhibitory effects of BMPER knock-
down and rosuvastatin on ALP activity were compared. 
Although both BMPER knockdown and rosuvastatin 
showed a significant inhibition of high glucose-increased 
ALP activity, there still existed a significant inhibitory 
effect of rosuvastatin (Fig.  6a, b). Collectively, these 
results suggest that there were at least two pathways in 
high glucose-increased ALP activity: the Rho–ROCK-
dependent pathway and the BMPER-dependent pathway.
Discussion
Critical role of the Rho–ROCK signaling pathway in high 
glucose‑induced ALP activation
Previous reports have shown high glucose induces osteo-
genic changes in vascular smooth muscle cells [25–27]. 
Moreover, it has been reported that statins show inhibi-
tory effects on TGF-β-induced [9], vitamin D3 and war-
farin combination therapy-induced [8], and inorganic 
phosphate-induced [6] trans-differentiation of cultured 
vascular smooth muscle cells, which is considered to 
reflect vascular calcification. However, as far as we know, 
whether statins inhibit high glucose-induced ALP acti-
vation has not been reported. Furthermore, we show 
here, for the first time, the increases in BMPER mRNA 
expression in vascular smooth muscle cells cultured in 
high glucose-containing media, and BMPER involvement 
in high glucose-induced ALP activation, independent of 
the Rho–ROCK signaling pathway. GGPP is synthesized 
from the combination of FPP and isopentenyl pyroph-
osphate (IPP) and because statins block the pathway 
upstream of these moieties, GGPP cannot be synthesized 
by treatment with statins even upon FPP supplementa-
tion, as IPP is not available [3]. The restoration of rosuv-
astatin-inhibited ALP activation in HCASMCs by GGPP, 
Fig. 4 Effects of rosuvastatin and ROCK inhibitors on BMPER mRNA levels. a Rosuvastatin did not inhibit increases in BMPER mRNA expression 
in aortas of STZ‑induced diabetic mice. The values represent the mean ± SEM (n = 9–11). b Rosuvastatin did not change BMPER mRNA levels 
in HCASMCs. HCASMCs and HUVECs were cultured with rosuvastatin in high glucose‑containing media for 2 days. The values represent the 
mean ± SEM (n = 4). c Fasudil and Y‑27632 did not change BMPER mRNA levels in HCASMCs cultured in high glucose‑containing media for 5 days. 
The values represent the mean ± SEM (n = 3). *P < 0.05; ns not significant.
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but not by FPP, suggests the involvement of GGPP-
dependent proteins such as Rho, Rac and Cdc42, rather 
than farnesylation-dependent proteins such as Ras. In 
line with this, ROCK inhibitors showed similar inhibi-
tory effects on high glucose-induced ALP activation in 
HCASMCs. Thus, the Rho–ROCK signaling pathway is 
critical for high glucose-induced ALP activation.
In contrast to the results of the present study, Trion 
et  al. showed a dose-dependent stimulatory effect of 
statins on calcification of vascular smooth muscle cells 
[28]. However, because in this study a 500 times higher 
concentration of atorvastatin was used than in Son et al. 
[6], who reported a protective effect of atorvastatin, 
calcification induced by the statin in the study done by 
Trion et al. may have resulted from apoptosis of vascular 
smooth muscle cells. In contrast to lipophilic statins like 
atorvastatin, hydrophilic statins such as pravastatin and 
rosuvastatin are reported to suppress apoptosis of vari-
ous cells [29]. Pravastatin suppresses apoptosis of vas-
cular smooth muscle cells [30–32], while rosuvastatin 
suppresses apoptosis of vascular endothelial cells [33], 
cardiomyocytes [34], and podocytes [35]. In the present 
study, we used rosuvastatin at the commonly-used con-
centration (10  µM), at which apoptosis does not occur, 
and therefore the rosuvastatin-induced suppression of 
the high glucose-increased ALP mRNA expression and 
activity was not due to apoptosis of HCASMCs.
Contribution of the Rho–ROCK signaling pathway 
and BMPER to high glucose‑induced ALP activation
Tonic ROCK mediated vasoconstriction contributes 
to coronary vasomotor tone in early diabetes [36], and 
diabetes-induced vascular dysfunction can arise via 
Fig. 5 Effect of BMPER knockdown on ROCK activity. HCASMCs were 
cultured in high glucose‑containing media for 10 days and MYPT1 
phosphorylation was examined. Representative results (a) and densi‑
tometry (b) are shown. The values represent the mean ± SEM (n = 3). 
*P < 0.05; ns not significant.
Fig. 6 Comparison of the inhibitory effects of BMPER knockdown 
with rosuvastatin on high glucose‑increased ALP activity. ALP 
activity of HCASMCs cultured with rosuvastatin, BMPER knock‑
down‑HCASMCs, and BMPER knockdown‑HCASMCs cultured with 
rosuvastatin was compared at day 10. Representative images of the 
ALP‑staining (a) and percentages of the ALP‑positive area relative to 
the total surface area of HCASMCs (b) are shown. The data are pre‑
sented as mean ± SEM (n = 4). *P < 0.05; †P < 0.01; ns not significant.
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inhibition of endothelial nitric oxide synthase caused 
directly or indirectly due to an up-regulation of ROCK 
by hyperglycemia [37]. Moreover, ROCK is substantially 
involved in the pathogenesis of coronary vasospasm, 
angina pectoris, hypertension, pulmonary hypertension, 
and heart failure [38]. Kawamura et  al. have reported 
that high glucose-increased osteopontin expression was 
mediated via the Rho–ROCK signaling pathway in vas-
cular smooth muscle cells [25]. We hypothesized that 
BMPER might be regulated by the Rho–ROCK signal-
ing pathway. However, ROCK inhibitors did not change 
BMPER mRNA expression. Moreover, BMPER knock-
down did not change MYPT1 phosphorylation. Collec-
tively, these results indicate that there are at least two 
independent pathways in high glucose-induced ALP 
activation: the Rho–ROCK signaling pathway and the 
BMPER-dependent pathway (Fig.  7). From our results 
we hypothesize that there may a possible new thera-
peutic strategy against vascular calcification, in which 
BMPER is inhibited. In addition, we have shown here 
that rosuvastatin and ROCK inhibitors did not have any 
effects on BMPER mRNA expression in HCASMCs. In 
contrast, it was reported that statins increased BMPER 
mRNA expression via the Rho–ROCK signaling pathway 
in HUVECs [24]. These conflicting results suggest that 
Bmper gene transcription might be differentially regu-
lated between HCASMCs and HUVECs.
Study limitations
There are two main limitations to the present study. 
First, ALP is an essential component of matrix vesi-
cles where it increases for the growth of hydroxyapa-
tite crystal [39]. Furthermore, tissue-nonspecific ALP is 
distributed in arteries, and is considered to be involved 
in vascular calcification [39]. We therefore used ALP as 
surrogate marker of vascular calcification. However, we 
only examined ALP mRNA levels in  vitro and in  vivo 
and ALP activity in  vitro, but did not evaluate calcium 
deposition in  vitro and vascular calcification in  vivo. It 
has been shown that calcification does not occur in aor-
tas of STZ-induced type I diabetic rats [40], as is the case 
with in our experiments. In addition, cultivation in high 
glucose-containing media does not show calcium deposi-
tion in  vitro [27]. Therefore, further studies using other 
animal models of vascular calcification are necessary to 
evaluate the roles of the Rho–ROCK signaling pathway 
and the BMPER-mediated signaling pathway in vascular 
calcification under diabetic conditions.
Another limitation is that in clinical studies whether 
statins can show an inhibitory effect on vascular calci-
fication is controversial. Kovarnik et al. assessed athero-
sclerotic plaques using virtual histology intravascular 
ultrasonography and showed that statins changed the 
plaques from fibrous and fibro-fatty plaques to necrotic 
plaques with calcification, suggesting that statins might 
enhance the density of calcification as part of a heal-
ing process [41]. The reason why statins did not show 
efficacy might be due to their lack of inhibitory effect 
on progressive calcification, generally detected in clini-
cal imaging, and therefore the starting point to treat 
might be too late. In the present study, rosuvastatin 
and BMPER knockdown inhibited ALP activation in 
HCASMCs, which might reflect a very early stage of vas-
cular calcification.
Conclusions
Targeting BMPER or BMPER-regulated signaling path-
ways in vascular smooth muscle cells might be a novel 
therapeutic target for prevention of vascular calcification.
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